Overactivity of the type I interferon pathway has been observed in several rheumatic conditions, including both monogenic diseases (for example, Aicardi-Goutieres syndrome (AGS) 1 ) and polygenic diseases (for example, systemic lupus erythematosus (SLE) [2] [3] [4] ). Human genetic studies of rheumatic diseases have identified numerous disease-risk genes that function within the type I interferon pathway. In many cases, these genetic variations augment the function of type I interferons. Data suggest that heterogeneity in type I interferon pathway activation and genetic make-up contribute to the clinical heterogeneity observed in rheumatic diseases 5 . Given that the type I interferon pathway is deeply entwined with the pathogenesis of multiple rheumatic diseases, a robust effort is underway to determine whether type I interferon activity might be a predictor of treatment response, or whether the type I interferon pathway could be targeted by treatment. It is attractive to think that differences in type I interferon-related genes and pathway activation between patients might lead to rational selection of immunomodulatory therapy.
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In this Review, we discuss the role of the type I interferon pathway in rheumatic diseases, focusing on the clinical implications. We briefly discuss type I interferon biology, followed by the interferon signature and other measurements of type I interferon in rheumatic diseases. We also examine genetic factors related to the type I interferon pathway, focusing on common gene variants associated with rheumatic disease, as well as the rare monogenic interferonopathies. We review current data regarding type I interferons in SLE, Sjögren syndrome, myositis, systemic sclerosis (SSc), and rheumatoid arthritis (RA). Finally, we consider treatments targeting type I interferons and the type I interferon pathway in rheumatic diseases.
Type I interferon biology
Interferons are functionally related cytokines that have important roles in infection, cancer, inflammation and autoimmunity. The antiviral properties of interferons were identified more than 50 years ago 6 , and the roles of interferons in cell survival, proliferation, differentiation and activation have since been highlighted and are reviewed elsewhere 7 . There are three major types of interferon: type I, type II and type III. Each type signals via a specific cell surface receptor complex. The type I interferons in humans include twelve interferon-α (IFNα) subtypes, IFNβ, IFNω, IFNκ and IFNε (reviewed elsewhere 8 ). Each subtype is produced by particular cells in response to specific stimuli. In this Review, we will focus on IFNα and IFNβ, the most extensively studied type I interferons in rheumatic diseases. environmental context. For example, pDCs constitutively express high levels of interferon regulatory factor 7 (IRF7), which, in part, enables them to produce relatively high amounts of IFNα 9, 10 , whereas other cell types must be 'primed' before high levels of type I interferons can be produced 10 . In a steady state, IFNβ is present at physiological levels, which seems to be important for priming cells for subsequent exposures 11, 12 . Of note, over the past 5-10 years there has been strong interest in the microbiome and its effect on inflammation and rheumatic diseases. Interestingly, commensal intestinal flora influence this baseline production of IFNβ 13 . Type I interferon production can be induced following the detection of microbial products by patternrecognition receptors (PRRs), such as Toll-like receptors (TLRs) or cytosolic nucleic acid sensors 14, 15 ; for example, lipopolysaccharide (LPS), a microbial cell wall component, is detected by surface TLR4; endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) are ligated by nucleic acids delivered to the endosome via immune complexes; and nucleic acids in the cytosol are detected by sensors such as retinoic acid inducible gene 1 (RIG-I, also known as DDX58), melanoma differentiation-associated protein 5 (MDA5, also known as IFIH1) and stimulator of interferon genes protein (STING) (FIG. 1) . In normal immune responses, these events occur after the sensing of pathogen-derived material. However, PRRs can also detect nucleic acids from endogenous sources (for example, nucleic acids within nucleic acid-containing antibody complexes, nucleic acids released as a result of defective nucleic acid metabolism 16 or reactivity with endogenous transcripts that contain virus-like nuclear repeat elements (NREs) 17 ) and might thereby contribute to the pathogenesis of rheumatic diseases. Interestingly, activation of the inflammasome can negatively regulate type I interferon production via the cyclic GMP-AMP synthase (cGAS)-STING pathway in the context of viral infection 18 . In normal conditions, cytosolic double-stranded DNA (dsDNA) triggers the synthesis of cyclic GMP-AMP (cGAMP) by cGAS, which activates STING, leading to type I interferon production. However, upon canonical and non-canonical inflammasome activation, caspase-1 cleaves cGAS and thereby dampens STING-mediated type I interferon production 18 . Interferon regulatory factors (IRFs) are activated downstream of PRRs, and translocate to the nucleus, where they function as transcription factors 19 .
In phagocytes and dendritic cells, stimulation of TLR3 or TLR4 leads to the activation of IRF3 via the adaptor TIR domain-containing adaptor molecule 1 (TICAM1, also known as TRIF) 20 . Activation of cytosolic nucleic acid sensors (MDA5 and RIG-I by RNA or STING by DNA) also upregulate the activation of IRF3 (REF. 21 ), which upregulates expression of IFNB1. The adaptor mitochondrial antiviral-signalling protein (MAVS) interacts with RIG-I and MDA5 to facilitate activation of IRF3 in phagocytic and dendritic cells, and of IRF7 in pDCs. In pDCs, recognition of nucleic acids by TLR7, TLR8 or TLR9 leads to recruitment of the adaptor protein MyD88, which in turn interacts with IL-1 receptorassociated kinase 1 (IRAK1) and IRAK4 (REF. 22) (FIG. 1b) . This signalling complex results in the phosphorylation of IRFs, such as IRF5 and/or IRF7. The translocation of IRF5 to the nucleus culminates in the transcription of genes encoding type I interferons, pro-inflammatory cytokines (IL-6 and TNF) and IL-12p40, whereas IRF7 promotes expression of type I interferons 23 . IFNβ production is also stimulated as a result of signalling through TNF receptors (TNFRs), such as receptor activator of nuclear factor-κB (RANK) and TNFR2. In macrophages and endothelial cells, TNF induces IFNβ production via IRF1, and can also induce an IFNβ autocrine loop that functions in synergy with canonical TNF signals to induce sustained expression of inflammatory genes and delayed expression of signal transducer and activator of transcription 1 (STAT1)-dependent interferon stimulated genes (ISGs) 24 (FIG. 1c) . This synergy primes macrophages for increased responses to subsequent challenges 24 . In human endothelial cells, this cascade seems to depend on TNFR2 and results in the promotion of monocyte recruitment 25 . Interaction between RANK and RANK ligand (RANKL) activates pathways that include TNFR associated factor 6 (TRAF6) and c-Fos, which promote expression of IFNβ and can also promote osteoclastogenesis (FIG. 1d) . IFNβ promotes the transcription of genes that inhibit c-Fos activity 26 and induce nitric oxide, which inhibits osteoclastogenesis 27 .
Type I interferon signalling
Type I interferons bind to a shared cell surface receptor, the type I interferon receptor (IFNAR). IFNα and IFNβ induce different conformational changes in the cytosolic portion of the receptor, which enables differential signalling by the two cytokines through the same receptor 28 . Upon engagement, IFNAR activates kinases (for example, Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) in canonical type I interferon signalling), prompting phosphorylation, dimerization and nuclear translocation of STAT proteins. The resulting STAT complexes control distinct gene-expression programmes. For example, the interferon-stimulated gene factor 3 (ISGF3) complex (composed of STAT1, STAT2 and IRF9) activates classic antiviral genes. By contrast, STAT1 homodimers induce pro-inflammatory gene expression, and STAT3 homodimers suppress pro-inflammatory gene expression 29 .
IFNα signalling activates antigen-presenting cells, and increases the expression of CD86, as well as MHC class I and II molecules on these cells, which provide
Key points
• Type I interferon has a pathogenic role in many rheumatic conditions, including systemic lupus erythematosus, Sjögren syndrome, myositis and systemic sclerosis. • Many genetic risk factors for rheumatic diseases lie within the type I interferon pathway as gain-of-function polymorphisms, and both polygenic and monogenic influences have been described. • Stratifying patients by type I interferon activity levels will inform us about both disease pathogenesis and treatment response in rheumatic diseases.
• A number of therapeutics that target type I interferons, the type I interferon receptor, or the type I interferon pathway are currently in various stages of development. . Thus, IFNα can bridge the innate and adaptive immune systems, demonstrating its importance in setting thresholds for self-reactivity and autoimmunity. IFNβ shares many downstream signalling properties with IFNα, but also has anti-inflammatory and antiproliferative properties. ISG expression is complex and seems to be cell and context dependent 31 (reviewed elsewhere 29 ). Signalling pathways that are also triggered by interferon receptor engagement (for example, mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB) and protein kinase B (RACα serine/threonineprotein kinase, also known as AKT) pathways) influence the transcription of ISGs and/or translation of ISG mRNA downstream of type I interferon-activated JAK-STAT pathways 32, 33 . Physiological activation of the type I interferon pathway is even more complex, as IFNβ can function in synergy with TNF, which is produced at early stages following innate recognition of a pathogen 34 . Co-stimulation with IFNβ and TNF induces a synergy-dependent delayed antiviral response via an as yet uncharacterized pathway that is dependent on TYK2, STAT2 and IRF9, but is independent of STAT1 signalling 34 . Thus, various cytokine signalling pathways functioning through different receptors can affect the outcome of type I interferon signalling.
Measuring type I interferon in blood
Traditionally, the term 'interferon signature' has been used to describe the pattern of increased expression of >100 type I ISGs in studies comparing the expression of genes in peripheral blood cells from patients with SLE and controls [2] [3] [4] . In addition to being present in SLE, such a signature has been found in other rheumatic diseases, including Sjögren syndrome, myositis, SSc and RA
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. An important caveat regarding the interferon signature is that genes that are type I interferon-induced can sometimes also be induced by other factors. For example, type II interferons can induce the expression of some of the same genes as type I interferons, and evidence is accumulating for a circulating type II interferon signature in SLE 36 . Many studies of the interferon signature have examined gene expression in either whole blood or in peripheral blood mononuclear cells (PBMCs) 2, 37 . In these approaches, multiple different cell types are mixed together. Different individuals typically have different proportions of immune cell types; thus, a difference in the amount of a measured transcript reflects a combination of the amount of transcript expressed by each cell type and the proportion of each cell type in the cellular mixture. This limitation can be partially addressed by enumerating the proportion of each immune cell type in the sample before study, although adjusting for these differences in cell numbers with covariates is also challenging and cannot account for every possibility in the data. To address this issue, individual immune cell populations can be sorted before lysing the cells and measuring gene expression 31, 38 . Interestingly, such analysis has shown that different immune cell types from the same blood sample express different ISGs 31 . These data suggest a great diversity in the downstream type I interferon responses of different cell types, and highlight the fact that we are still just beginning to understand the varied consequences of chronic type I interferon stimulation in human cellular immunity.
To address the limitations of interferon signature studies, functional assays have also been used to assess type I interferon activity in large cohorts of patients 39 43 . Additional validation of this technology is anticipated in the future. . When IFNα therapy is stopped, the rheumatic symptoms usually improve, supporting a causal role for type I interferons in the initiation of SLE in some patients 45 . Circulating type I interferon activity is frequently high in unaffected relatives of patients with SLE and familial correlations in type I interferon activity have been observed 46, 47 , suggesting that high levels of type I interferon in the circulation is a heritable risk factor for SLE. This heritability of high levels of type I interferon activity is shared across patients with SLE from all ancestral backgrounds 46 and follows a polygenic inheritance pattern. In longitudinal studies of serum samples from patients before they were diagnosed with SLE, type I interferon activity increases precipitously in the year before disease onset 48 , also supporting the importance of type I interferon in disease initiation in SLE.
Genetic factors
Among the SLE-associated loci identified in case-control genetic studies, there is an over-representation of genes involved in type I interferon signalling, production and response 49 . In general, many of the SLE-associated variants in type I interferon pathway genes are associated with increased activity in the type I interferon pathway in humans (reviewed elsewhere 49 ). Variants have also been associated with increased circulating type I interferon activity or increased ISG expression 50, 51 . Genes that are overexpressed in peripheral blood cells (creating the interferon signature) are not necessarily the same as the genes that are implicated as genetic risk factors 5 . 59 . In SLE, risk variants of IRF5 are associated with increased circulating type I interferon activity in patients with SLE; this association is dependent upon the presence of anti-RNA-binding protein (RBP) or anti-dsDNA autoantibodies 60, 61 . These data suggest that IRF5 risk variants might be an important factor in the 'stimulated' scenario, in which the autoantibody immune complexes provide a constant endogenous stimulus that synergizes with a hyperresponsive TLR system, resulting in chronic over-production of type I interferons. The SLE IRF5 risk haplotype is associated with the production of autoantibodies in otherwise healthy individuals 62 , suggesting a potential feed-forward loop. In such a loop, an IRF5 risk variant predisposes individuals to the production of autoantibodies, possibly via hyperactivity of the TLR pathway in B cells, and the autoantibodies produced can then form nucleic acid immune complexes that stimulate the overactive TLR system in innate immune cells. Genetic variants in both IRF7 and IRF8 have been associated with an increased risk of SLE 55, 63, 64 , and such variants are also associated with altered type I interferon responses in patients with SLE 23, 65, 66 .
Other interferon-related genes. Beyond the IRF family, a number of other genes associated with risk of SLE (for example, STAT4, MAVS, IFIH1 (which encodes MDA5) and PTPN22) have also been demonstrated to alter type I interferon pathway function 50,51, [67] [68] [69] . Variants in some of these genes have also been associated with other rheumatic diseases, for example, STAT4 is associated with Sjögren syndrome 70 , SSc 71 , RA 72 , psoriasis 73 and, possibly, JIA 74 ; IFIH1 is associated with late-onset psoriasis 75 ; and PTPN22 is associated with RA and JIA 76, 77 . Overall, type I interferon activity is clearly controlled to some degree by genetic factors and is a polygenic trait.
Interestingly, thus far, robust evidence demonstrating gene-gene interactions between interferon pathway genes (that is, the effect of one gene being modified by one or several interferon pathway genes) is lacking. Studies that have examined type I interferon in patients in the context of these risk variants have demonstrated additive effects without evidence for either synergy or redundancy to date 50, 51, 65 . In addition, other factors, such as epigenetic regulation 78 , probably influence the effect of these risk variants.
Tissue expression. Most studies in SLE have examined circulating type I interferons, however, the action of type I interferons in the tissue is likely to be important and complex. Genetic polymorphisms in IFNK (encoding IFNκ) are implicated in the pathogenesis of cutaneous lupus erythematosus, and disease associated single-nucleotide
Box 1 | Functional assays of type I interferon activity
The most well-known functional assays for measuring type I interferon activity are the luciferase 203 and WISH cell 124 reporter assays. Both reporter assays rely on a cell line bearing the receptor for type I interferon.
Luciferase reporter assay
The luciferase assay uses a cell line that is transfected with a plasmid carrying the luciferase gene under the control of a type I interferon inducible promoter. The cell line is exposed to samples containing type I interferon, and type I interferon activity is determined by measuring the luciferase expression 203 .
Wish cell reporter assay
The WISH cell assay uses the WISH epithelial cell line to measure the ability of patient sera to promote type I interferon-induced gene expression. WISH cells are exquisitely sensitive to type I interferon, but do not produce type I interferons and lack other pattern recognition receptors such as TLRs 204, 205 . Expression of the interferon stimulated genes (ISGs) MX1, IFIT1 and EIF2AK2 is measured using quantitative PCR (qPCR). The relative expression of each of these three genes is standardized to that generated with healthy donor sera and summed to generate a score reflecting the ability of sera to cause interferon-induced gene expression, which is referred to as type I interferon activity. The type I interferon activity is reflective of the amount of type I interferon protein present in the sample to ligate the type I interferon receptor. Additional aliquots from the same patients can be tested following pre-incubation with anti-IFNα or anti-IFNβ antibodies to determine how much of the total type I interferon activity is due to IFNβ activity, and how much is due to IFNα activity. IFNγ, TNF, IL-6, and IFNλ do not induce substantial expression of these three transcripts in the WISH cells (REF. 124 and unpublished data).
polymorphisms in IFNK differ between male and female patients 79 . Interestingly, type I interferon activity was frequently increased in the circulation of female patients with such IFNK variants compared with that in healthy controls 79 . However, IFNκ was not a major contributor to the type I interferon activity observed in the circulation of these patients 46, 79 . The IFNK variants could instead be influencing type I interferon production by pDCs in the affected skin, and thereby increasing type I interferon activity in the circulation 79 . Keratinocytes from the skin of patients with cutaneous lupus erythematosus produce more IL-6 in vitro than keratinocytes from healthy individuals after exposure to TLR agonists or ultraviolet B (UVB) radiation; this increased IL-6 production seems to be dependent on IFNκ 80 . Such cytokine production might also contribute to the skin inflammation observed in cutaneous lesions in SLE.
Heterogeneity in SLE
IFNα is the predominant circulating type I interferon in patients with SLE 46 . Serum IFNα activity varies widely between patients with SLE, and in 40-50% of patients, serum IFNα activity is normal 46 . Therefore, type I interferon is probably not an important pathogenic factor for all patients with SLE, contributing to the pathological heterogeneity of this disease. A high degree of functional circulating type I interferon activity is strongly correlated with the presence of anti-RBPs, such as antibodies to 52 kDa SSA/Ro antigen (Ro52, also known as TRIM21) and ribonucleoprotein (RNP), in patients with SLE 39 . These autoantibody titres frequently do not change considerably over time, supporting the idea of a stable subset of patients with SLE who have high levels of type I interferon activity. A study comparing gene expression in African American and European American patients with SLE demonstrated that patients from both ancestral backgrounds had a type I interferon signature, but in African Americans this signature was particularly dependent on the presence of anti-RBP autoantibodies 81 . This finding is interesting as these autoantibodies, particularly anti-RNP and anti-Sm antibodies, are more common in African American patients than in European American patients 39 , suggesting differences in the molecular pathogenesis of SLE between ancestral backgrounds.
Case-case genome-wide genetic studies, which compare patients with high levels of type I interferon activity to those with low levels of type I interferon activity, have implicated additional genes that modulate circulating IFNα activity in patients with SLE 5, 47 . These studies identified a number of novel loci associated with risk of SLE and high degree of type I interferon activity that were not identified in case-control studies, including risk loci in PRKG1, PNP, and ANKS1A 5, 47 . Further bioinformatic analyses suggested that these loci mediate functional effects in DCs and natural killer (NK) cells 5 . NK cells cooperate with DCs to induce IFNα production in SLE 82 . The PNP variant is a loss-of-function mutation in the gene encoding purine nucleoside phosphorylase (PNP), an enzyme involved in purine metabolism, that leads to cell-cycle abnormality (a block in S phase entry) and type I interferon pathway activation in human lymphocytes 83 . Interestingly, this block in S phase can be rescued in vitro by providing hypoxanthine and adenosine, supporting the notion that relative PNP deficiency is the cause of the S-phase block, and suggesting a potential for personalized therapeutics in patients with SLE who harbour this PNP variant 83 .
Clinical implications
In SLE, the peripheral blood type I interferon signature correlates with disease severity 2 . In a cross-sectional study, patients with a prominent peripheral type I interferon signature fulfilled a substantially higher number of SLE clinical diagnostic criteria and, upon retrospective review, more commonly had kidney, central nervous system (CNS) and/or haematologic involvement at some point during the course of their disease 2 . However, in longitudinal studies, the interferon signature in blood is relatively stable and cannot be used to predict SLE disease flares over time 84, 85 . The expression of certain chemokines (CXC-chemokine ligand 10 (CXCL10), CC-chemokine 2 (CCL2), and CCL-chemokine ligand 19 (CCL19)) that are induced by interferons and other cytokines also correlate with disease activity and might predict risk of flares over time in SLE 86 , suggesting that other factors beyond type I interferon are involved in disease flares. Gene expression studies support this idea, showing that other non-type I interferon-induced gene signatures, such as the plasmablast signature, correlated more strongly with disease activity than the interferon signature 37 . Thus, type I interferons might be more important in disease initiation and in the early phases of disease than in disease flares.
Type I interferon in Sjögren syndrome
Some of the genes associated with increased type I interferon pathway activation in SLE (such as IRF5 and STAT4) are also associated with risk of Sjögren syndrome 56 , and a type I interferon signature has been reported in both the blood and tissues of patients with Sjögren syndrome [87] [88] [89] . In Sjögren syndrome, a peripheral blood type I interferon signature strongly correlates with the presence of anti-SSA/Ro antibodies 88 , which parallels the association observed between anti-RBP antibodies and the interferon signature in SLE. Thus, despite the many clinical differences that exist between Sjögren syndrome and SLE, parallels can be drawn between these two diseases regarding type I interferon pathway activation with respect to autoantibody associations and background genetics. Although anti-SSA/Ro antibodies are associated with increased type I interferon activity in patients with either SLE or Sjögren syndrome, asymptomatic individuals with high anti-Ro antibody titres do not have high levels of circulating type I interferon activity 90 . This finding suggests that other disease-associated factors must be present in addition to anti-SSA/Ro antibodies to cause a chronic increase of circulating type I interferon 90 .
In Sjögren syndrome, a type I interferon signature might help identify clinically meaningful subgroups of patients. A peripheral blood monocyte type I interferon signature identified a subgroup of patients with Sjögren syndrome who had high levels of clinical disease activity, autoantibodies and the expression of B-cell activating factor (BAFF, also known as TNFSF13)-encoding mRNA in their monocytes 91 . OAS1, one of the ISGs, is a Sjögren syndrome risk locus, and disease-associated variants of OAS1 result in alternate splicing of the gene transcript, leading in multiple alternative transcripts that result in a lack of translational response to type I interferon stimulation 92 . The 620W polymorphism in PTPN22 is also associated with Sjögren syndrome and with a low expression of ISGs, implying the presence of distinct genetic backgrounds among subsets of patients with Sjögren syndrome that can be defined by type I interferon activity 93 . Interestingly, investigators found that the pattern of expression of RNA-sensing receptors (TLR7, RIG-I and MDA5) in monocytes and pDCs from patients with Sjögren syndrome differed substantially between those who did and did not have a peripheral type I interferon signature 94 . This type of differentiation might help identify subsets of patients who will benefit from therapies targeting these pathways.
In contrast to the type I interferon signature that predominates in the blood in patients with Sjögren syndrome, a type II interferon signature predominates in minor salivary gland (MSG) biopsy samples from such patients 95 . Concomitant low expression of IFNα-encoding mRNA and high expression of IFNγ-encoding mRNA in MSG tissue is strongly associated with lymphomagenesis, suggesting that the ratio between these two mRNA species in MSG biopsy samples can serve as a biomarker for in situ Sjögren syndrome-related lymphoma 95 .
Type I interferon in myositis
In patients with either dermatomyositis or polymyositis, type I interferon levels are increased in the circulation and a type I interferon signature is detectable in muscle tissue 35, 96, 97 . Muscle tissue from patients with juvenile dermatomyositis has increased numbers of infiltrating pDCs and increased expression of the ISG MX1 98 compared with tissue from healthy controls. Multiple studies have shown an association between type I interferon in the circulation and disease activity in myositis 96, 99, 100 . These studies provide stronger evidence for an association between type I interferon activity and longitudinal disease activity than has been observed in SLE.
Although the genetic basis of inflammatory disease is currently less well described in myositis compared with SLE, a number of polymorphisms in several genes associated with increased type I interferon activity in patients with SLE (for example, OPN rs28357094G and TNFA-308A alleles) have been associated with high levels of type I interferon activity in patients with dermatomyositis 101 . Furthermore, type I interferon levels are higher in patients with dermatomyositis who have a family history of SLE compared with in those without a family history of SLE 102 , which supports the idea of a shared genetic basis for type I interferon pathway activation in various rheumatic diseases. The presence of anti-RBP antibodies in patients with myositis, such as anti-SSA/Ro and anti-Sm antibodies, is associated with high levels of circulating type I interferon activity 103 , paralleling that seen in other rheumatic diseases.
Interestingly, the use of TNF inhibitors in patients with myositis 104 or Sjögren syndrome 105 results in increased type I interferon activity, which, in myositis, is associated with lack of improvement or worsening of disease 104 . Circulating IFNα is an important contributor to the total functional type I interferon activity observed in dermatomyositis 96 ; however, some studies support the idea that IFNβ also contributes to the interferon signature seen in PBMCs from patients with dermatomyositis 106 . TLR3 stimulation of cultured myoblasts induces the production of IFNβ when combined with IFNγ stimulation, and upregulates the expression of HLA class I molecules 107 . In muscle biopsy samples from patients with polymyositis or dermatomyositis, immature muscle precursor cells that overexpress HLA class I are a source of IFNβ 107 . Thus, IFNβ from immature muscle precursor cells might contribute to the type I interferon signature seen in muscle tissue in myositis. A 2015 study of muscle tissue from patients with dermatomyositis demonstrated that TLR3 and RIG-I are preferentially expressed in the perifascicular fibres, indicating that these type I interferon pathway components might be involved in the formation of perifascicular atrophy, a hallmark feature of dermatomyositis 108 . In the same study, the investigators found that expression of TLRs and RIG-I was upregulated in the muscle tissue of patients with dermatomyositis compared with controls (which included patients with polymyositis, facioscapulohumeral muscular dystrophy, and patients without neuromuscular disease) and that TLR4 and TLR9 were expressed mainly in inflammatory infiltrates 108 . The researchers concluded that endo genous production of type I interferon in dermatomyositis is generated by pDCs, mainly through the TLR9 pathway. However, the TLR4 pathway can also contribute to type I interferon induction 20 (FIG. 1a) , and as TLR4 was also expressed in the inflammatory infiltrates, it is conceivable that TLR4 might also contribute to the endogenous type I interferon found in the muscle of patients. Additionally, non-immune cells that produce IFNβ (such as endo thelial cells , FIG. 1c) might also contribute to type I interferon production in myositis.
Type I interferon in SSc
A number of studies have documented increased type I interferon-induced gene expression in patients with SSc, in both circulating blood cells and in affected lung tissue [109] [110] [111] [112] . Interestingly, patients with SSc who have anti-SSB/Ro antibodies are more likely to have high levels of type I interferon than patients without these anti bodies, resembling associations seen in myositis, Sjögren syndrome and SLE 113 . Other autoantibodies have also been associated with high circulating type I interferon expression in SSc, including anti-U1 RNP and antitopoisomerase autoantibodies 109 . This finding suggests that a similar process of immune complex-mediated type I interferon generation might contribute to the increased circulating type I interferon levels observed in many rheumatic diseases.
A are associated with SSc. pDCs are also implicated in SSc pathogenesis. In SSc, in addition to the role of pDCs in type I interferon production, there is a striking and disease-specific over-production of CXC-chemokine ligand 4 (CXCL4, also known as platelet factor 4) by pDCs, which corresponds with severe skin disease and lung fibrosis 117 . CXCL4, a potent antiangiogenic chemokine that also has profibrotic properties and stimulates the proliferation of regulatory T cells that have impaired function [118] [119] [120] , is suspected to have a major role in the vasculopathy of SSc and to influence fibrosis by downregulating FLI1 in endothelial cells and fibroblasts 117 . It is speculated that CXCL4 does not act in isolation 117 ; hence other factors, such as alterations in the type I interferon pathway, could function together with CXCL4 to contribute to SSc pathogenesis. Intramuscular administration of recombinant IFNα showed some initial promise in improving or stabilizing skin scores in a pilot study of patients with diffuse cutaneous SSc 121 . However, in keeping with IFNα having a pathogenic role in SSc, a randomized, double-blind, placebo-controlled trial showed that recombinant IFNα therapy in SSc is ineffective and might in fact be harmful, as those who received the IFNα treatment showed less improvement in skin scores and greater deterioration of lung function than the placebo group 122 . Type I interferon in RA A type I interferon signature is detectable in the peripheral blood of patients with RA, and can be present in the preclinical phase of the disease 123 . The relative level of expression of ISGs in the circulation in RA is lower than that observed in SLE and other autoimmune connective tissue diseases 35, 124 . However, some of the genes associated with increased type I interferon pathway activation in SLE are also associated with the risk of RA, such as IRF5 ( (REF. 77 ). The finding that particular polymorphisms are associated with the risk of developing a number of rheumatic diseases supports the idea that there is a shared pathway in these diseases 126 . The presence of pDCs and the expression of ISGs, IFNα and IFNβ have been documented in the synovium of patients with RA [127] [128] [129] [130] . IFNα positively correlates with TLR3 and TLR7 in the lining and sub-lining of RA synovium. IFNα increases the expression of TLR3 and TLR7 and downstream production of IL-6 and TNF. Additionally, IFNα markedly potentiates TLR4-mediated production of IL-1β and IL-18 in synovial cells from patients with RA 130 . By contrast, IFNβ has an anti-inflammatory effect in inflammatory arthritis. In PMBCs, IFNβ can inhibit the production of IL-1β and TNF and can also increase the production of IL-1 receptor antagonist (IL1Ra) in a dosedependent manner 131 . IFNβ also dose-dependently increases IL1Ra secretion by synovial fibroblasts and enhances the secretion of IL1Ra induced by IL1β in synovial fibroblasts and chondrocytes 132 . Treatment with IFNβ is effective in alleviating arthritis in the collagen-induced arthritis mouse model of RA 133, 134 . However, in a multicentre, randomized, double-blind, placebo-controlled phase II study, treatment with subcutaneous recombinant IFNβ resulted in no improvement in patients with active RA 135 . In RA, type I interferon is potentially a predictive biomarker of response to biologic therapies. For example, the presence of a pretreatment type I interferon signature reportedly predicts response to the B cell-depleting therapy rituximab 136 . In another study, the ratio of pretreatment IFNβ activity to IFNα activity (IFNβ:IFNα activity ratio) could predict the response to anti-TNF therapy in RA 137 . A larger study from 2016 supported this idea, finding that the pretreatment serum IFNβ:IFNα activity ratio was strongly predictive of non-response to TNF inhibitors in both discovery and independent replication cohorts 138 . Although the reasons for the differences in the relative proportions of IFNα versus IFNβ in the circulation are unknown, other studies support the idea that these two type I interferons exist in different proportions in different rheumatic diseases 139 , with IFNα predominating in the circulation in SLE 46,96 , and IFNβ being relatively more abundant in RA 138, 139 . Reason for the discrepancy between the finding that IFNβ was anti-inflammatory in early functional studies [131] [132] [133] [134] 140 and the failure of the clinical trial of recombinant IFNβ treatment 135 , as well as the relatively increased IFNβ levels observed in the circulation of patients with RA who are unlikely to respond to anti-TNF therapy 138 , is unclear. Given the complexity of type I interferon signalling regulation (reviewed elsewhere 29 ), the effects of IFNβ are probably influenced by the amount, duration and location (for example, the circulation or tissue) of IFNβ expression, and the environmental context.
Monogenic interferonopathies
The gene variants mentioned thus far moderately effect activation of the type I interferon pathway and/or susceptibility to complex polygenic rheumatic diseases, and it is likely that combinations of these genetic variations are probably required to predispose to disease. However, a number of monogenic diseases are characterized by interferon pathway activation. Interestingly, these diseases are considered to lie on an autoimmuneautoinflammation spectrum that depends on the driver of dysregulated type I interferon production 141 . On the basis of this spectrum, Kim et al. 141 have proposed grouping these conditions into 'autoinflammatory' interferonopathies (those caused by a problem in the innate immune sensing system), and 'autoimmune' interferonopathies (those caused by immune complex stimulation of endosomal TLRs in B cells and pDCs). Dysregulation can occur from both processes in a given patient; however, the initial 'driver' of the interferonopathy is typically at one end of this spectrum. Monogenic forms of SLE (such as those caused by loss-of-function mutations in the genes encoding complement protein C1q, deoxyribonuclease 1 or deoxyribonuclease-γ) are considered to be autoimmune monogenic interferonopathies. Important examples among the autoinflammatory monogenic interferonopathies include AGS, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), and STING-associated vasculopathy with onset in infancy (SAVI).
AGS and related monogenic diseases
AGS is caused by gain-of-function mutations in TREX1 or IFIH1. The TREX1 gene encodes the major mammalian 3ʹ−5ʹ DNA exonuclease that degrades endogenous DNA in the cytoplasm 142 . In addition to AGS 143, 144 , mutations in TREX1 have also been reported in SLE 143, 145 , familial chilblain lupus 144 and retinal vasculopathy with cerebral leukodystrophy (RVCL) (reviewed elsewhere 146 ). AGS and RVCL are characterized clinically by CNS inflammation and high levels of type I interferon in the circulation and cerebrospinal fluid. Mutations in the gene encoding nucleic acid sensor RIG-I, DDX58, cause an atypical Singleton-Merten syndrome, which manifests with variable clinical presentations of glaucoma, aortic calcification and skeletal abnormalities, such as acro-osteolysis without dental anomalies 147 . Although there are no classical signs of apparent inflammation in patients with Singleton-Merten syndrome, the clinical manifestations are suspected to relate to chronic inflammation, at least in part conferred by constitutive activation of RIG-I resulting in increased type I interferon activity and ISG expression. CANDLE CANDLE is caused by mutations in protein subunits of the proteosome-immunoproteasome system. Disease can be the result of any of several recessive mutations in different protein subunits of the system, located either in one single subunit (monogenic, homozygous or compound heterozygous inheritance) or in two different subunits (digenic and compound heterozygous inheritance) 148, 149 . Defects in the catalytic activity of the proteasome-immunoproteasome system result in a sustained production of type I interferon 148, 149 that is independent of STING and MAVS 141 . SAVI SAVI is caused by gain-of-function mutations in STING and is characterized by cutaneous vasculopathy and pulmonary inflammation 150 . In vitro studies indicate that these STING variants stimulate IFNB1 expression and other gene targets of STING 150 . Data from STING N153S knock-in mice demonstrates that at least some of the phenotype of SAVI occurs independently of IRF3, suggesting that the phenotype is not solely ISGrelated 151 . However, patients with SAVI have a strong type I interferon signature in their PMBCs, and JAK inhibitors reduce the constitutive upregulation of phosphorylated STAT1 in the lymphocytes of these patients in vitro, indicating that JAK inhibition could be a promising therapy for SAVI 150 .
Type I interferon pathway therapies
Insights gleaned from studies of the type I interferon pathway, including those identifying disease risk loci and functional studies of molecules involved in the type I interferon pathway, might help explain the heterogeneity in the molecular pathogenesis of rheumatic diseases. Such insights might explain some of the heterogeneity in treatment responses observed in these diseases, and type I interferon pathway studies could also reveal new targets. These insights should inform the development of new therapies and the design of clinical trials. Multiple anti-IFNα, anti-IFNAR and anti-TLR strategies are currently in clinical development for the treatment of rheumatic diseases (TABLE 1) .
Anti-IFNα therapies
Anti-IFNα monoclonal antibodies (such as sifalimumab and rontalizumab) can inhibit the expression of the type I interferon signature in patients with SLE [152] [153] [154] , and phase II studies examining clinical responses to these antibodies in patients with SLE have had mixed results [155] [156] [157] . Rontalizumab did not meet the primary endpoint in one phase II trial, but did demonstrate some efficacy in a subset of patients with SLE and a low type I interferon signature metric (a set of 3 ISGs (HERC5, EPSTI and CMPK2) were used as a surrogate for the type I interferon signature) 157 . Treatment with sifalimumab did result in clinical improvement in various clinical end points in patients with SLE in another phase II study, and the effect was strongest in those patients with a high type I interferon signature score (based on a set of four ISGs: IFI27, IFI44, IFI44L and RSAD2) 156 . Although these phase II trial findings seem somewhat contradictory, it is interesting that in both trials the pretreatment type I interferon status of the patients affected the treatment response to anti-IFNα antibodies. It is possible that differences in the strength of interferon blockade between the two therapeutics or the dosing level could explain these differences in clinical efficacy.
Results from phase I and II studies investigating the induction of humoral polyclonal anti-IFNα responses by immunization with IFNα kinoid (a conjugate of an inactive form of human IFNα and a carrier protein, keyhole limpet haemocyanin) in patients with SLE have also shown some promise in improving control of the disease 158 . Furthermore, in a phase Ib trial, sifalimumab reduced the expression of a type I interferon signature observed in the blood of patients with dermatomyositis or polymyositis 159 .
Anti-IFNAR therapies
Anifrolumab is an antibody that binds to the IFNAR and blocks signals from both IFNα and IFNβ 160 . In a phase II study of patients with moderate to severe SLE 161 , anifrolumab treatment resulted in greater rates of improvement across a broad range of composite and organ-specific disease activity measures; a greater proportion of patients achieving and maintaining low disease activity or corticosteroid tapering as well as a trend toward a reduction in flare rate compared with placebo. Greater efficacy was seen in all end points in patients with a high baseline type I interferon signature compared with those with a low baseline interferon gene signature, suggesting that the former group represents a subpopulation of patients who are likely to benefit from anifrolumab treatment. However, the sample size of the low baseline type I interferon signature group was small, limiting interpretations of the data from this group; thus, further studies are warranted to determine efficacy in this subpopulation.
In early phase studies in patients with SSc, anifrolumab inhibited a type I interferon signature (as measured by a composite score from five ISGs: RSAD2, IFI44, IFI44L, IFI27 and IFI6), and this inhibition correlated with decreases in T cell-related transcripts and increases in collagen degradation-related transcripts in the skin 162 . Thus far there have not been overly concerning safety signals with regard to viral infection or malignancy risk with these anti-IFNα and anti-IFNAR therapies, although herpes zoster reactivation has occurred in some patients 161 .
In lupus-prone mice, type I interferon-induced synapse loss and behavioural phenotypes are prevented by blocking signalling at IFNAR 163 , suggesting that anifrolumab might be helpful in treating neuropsychiatric lupus and should be considered for future clinical trials.
Hydroxychloroquine and TLR inhibition
Treatment with hydroxychloroquine impairs the ability of pDCs from patients with SLE to produce IFNα and TNF in response to stimulation with TLR9 and TLR7 agonists in vitro 164 . Unless contraindicated, hydroxychloroquine is advocated for use in all patients with SLE owing to its efficacy in reducing the number and intensity of flares, and in reducing damage accrual 165, 166 . In the treatment of RA, hydroxychloroquine has also been used in combination with other drugs (for example, the widely use combination of methotrexate plus sulfasalazine and hydroxychloroquine, known as the 'triple therapy' regimen); however, hydroxychloroquine has limited efficacy in treating disease activity on its own. In a 2017 systematic review and meta-analysis of studies evaluating the effects of hydroxychloroquine on cardio vascular outcomes in patients with RA, hydro xychloroquine seemed to decrease insulin resistance and incidence of cardiovascular disease; however, the data were too few for meta-analysis 167 . , and a humanized anti-TLR4 monoclonal antibody is currently being tested in phase II of trials for the treatment of RA
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. TLR4 inhibition could be interesting in RA if TLR4 activation contributes to the IFNβ levels observed in this disease, which is associated with non-response to anti-TNF therapies.
Kinase inhibition
The development of small molecule kinase inhibitors that target proteins in the type I interferon pathway has been a major area of drug development, and a number of clinical trials of these inhibitors in various rheumatic diseases are currently underway (TABLE 2) .
Tofacitinib, a JAK1 and JAK3 inhibitor, was approved by the FDA in 2012 for the treatment of patients with RA who have had an inadequate response or intolerance to methotrexate. Tofacitinib is now being tested in phase III trials for use in other rheumatic diseases (such as JIA [175] [176] [177] and psoriatic arthritis 178-180 ), and is being investigated in earlier phases studies for use in SLE 181-183 and dermatomyositis 184 . Baricitinib, a JAK1 and JAK2 inhibitor, is being evaluated in stage III trials for the treatment of RA [185] [186] [187] [188] [189] [190] , in addition to being used as part of a compassionate use protocol for the treatment of autoinflammatory syndromes marked by high type I interferon (for example, SAVI, AGS and CANDLE) 191 . JAK inhibitors that also inhibit TYK2 are in phase II trials for the treatment of RA [192] [193] [194] [195] [196] [197] , psoriatic arthritis 198, 199 and membranous lupus nephritis 200 . Finally, an IRAK4 inhibitor is currently in phase II trials for the treatment of RA 201 . Kinase inhibitors are also being tested in additional chronic autoimmune or autoinflammatory diseases not covered in this Review (TABLE 2) . 156, 157 , but this same strategy might also yield informative results in the treatment of other rheumatic diseases with either therapies that target the type I interferon pathway or other drugs.
Stratifying patients by type I interferon pathway activity might reveal important differences in particular subgroups of patients that would otherwise be missed and might also enable the prediction of a patient's treatment response to particular therapies, such as that observed with anti-TNF therapy 138 . Monitoring type I interferons during treatment might also be desirable in some patients. For example, caspase inhibitors are an attractive therapy for use in autoinflammatory disorders that result in increased inflammasome activation, such as NLRC4-related macrophage activation syndrome (NLRC4-MAS, also known as syndrome of enterocolitis and autoinflammation associated with mutation in NLRC4 (SCAN4)). However, blocking caspase-1 activity also pathologically increases type I interferon production in some patients (particularly those who have relatively high levels of type I interferon activity at baseline) 18 . Regular assessment of type I interferon pathway activation could enable better monitoring for possible unwanted consequences in this scenario.
Interestingly, many rheumatic diseases are more frequent in females than in males. In a 2017 transcriptome analysis of human skin samples, the genes that were overexpressed in female healthy skin (compared with male healthy skin) were frequently genes that are associated with autoimmune diseases such as SLE, SSc and Sjögren syndrome 202 . The presence of sex hormones, such as oestradiol or testosterone, did not affect the expression of these genes in cultured keratinocytes. Some of these overexpressed genes were regulated by the transcription cofactor vestigial-like protein 3 (VGLL3), the expression of which also has a strong female bias. ISGs (LY6E, OAS1, MX1 and IFI44) were among the genes that were targeted by VGLL3. In monocytes, maximal induction of the ISGs identified required the expression of VGLL3, suggesting that VGLL3 might promote inflammation by supporting type I interferon responses 202 . Thus, as we move towards precision medicine, we will need to carefully consider whether it is best to also subset patients with sex-discordant rheumatic diseases by sex in clinical trials.
Conclusions
The type I interferon pathway is central in both immunity and tolerance, and alterations in this pathway underlie the pathogenesis of different rheumatic conditions. Rheumatic diseases such as SLE, SSc, myositis and RA are heterogeneous and some of the differences observed between patients with rheumatic diseases could be explained by variations in the expression of interferon-related genes or activation of the type I interferon pathway. Hence, certain genetic factors and/or pathogenic pathways might explain particular disease phenotypes, and these underlying factors and/or pathways will not be shared between all patients who have the same rheumatic disease. We suspect variation in the type I interferon pathway is a major factor in the currently unexplained heritability of rheumatic disease.
Studies that compare patient subgroups based on their type I interferon signature or type I interferon activity have furthered our understanding of the molecular mechanisms underpinning the heterogeneity of these diseases and treatment responses. Additional molecular phenotyping should help to further advance our understanding of the pathogenesis of disease subtypes, and help to guide therapy. For example, medications that have seemingly failed in clinical trials of a complex rheumatic disease might still be helpful for treating a subgroup of patients with this disease. Thus, the study of individual samples from clinical trials is important, and insights gleaned from such studies should inform the next steps in an iterative fashion, including the subgrouping of patients by molecular phenotype in subsequent trials.
Functional studies of causal allelic variants should advance our ability to translate genetic associations into clinical applications. A delicate balance exists between the autoimmune and/or autoinflammatory effects and the antipathogen and anticancer effects of type I interferon. Increasing our understanding of the regulation of this pathway in humans will have important therapeutic and safety implications. By understanding the genetic regulation and molecular underpinnings of type I interferon in rheumatic diseases, we might be able to intervene therapeutically in a more personalized fashion, on the basis of the molecular dysregulation present in a given individual. 
